Sunshine Biopharma (SBFMW) Asset Writedowns and Impairment (2025)
Sunshine Biopharma (SBFMW) reported Asset Writedowns and Impairment of $131788.0 for Q4 2025, down 76.24% quarter-over-quarter from $554650.0 in Q3 2025.
Sunshine Biopharma (SBFMW) Asset Writedowns and Impairment (2025) Analysis & Trends
Sunshine Biopharma has reported Asset Writedowns and Impairment for 1 years, with the latest figure at $131788.0 in Q4 2025.
- For the quarter ending Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $131788.0; the trailing twelve-month figure through Dec 2025 stood at $1.7 million (changed N/A YoY), and the FY2025 full-year result was $1.7 million, changed N/A from the prior year.
- Asset Writedowns and Impairment for Q4 2025 stood at $131788.0, down from $554650.0 in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $1.1 million in Q2 2025, with the low at $131788.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.97 Bn | 36.23 Bn | 1.97 Bn |
| 2 | Zoetis | 33.59 Bn | 31.65 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn |
| 4 | Neurocrine Biosciences | 16.10 Bn | 14.78 Bn | 800.70 Mn |
| 5 | Aurora Cannabis | 15.56 Bn | 15.47 Bn | 21.72 Mn |
| 6 | Elanco Animal Health | 12.04 Bn | 11.61 Bn | 785.00 Mn |
| 7 | Alkermes | 7.36 Bn | 6.84 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.74 Bn | 6.24 Bn | 230.92 Mn |
| 9 | Liquidia | 6.27 Bn | 6.04 Bn | 121.79 Mn |
| 10 | Sunshine Biopharma | - | - | 2.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 131,788.00 |
| Dec 31, 2025 | 131,788.00 |
| Sep 30, 2025 | 554,650.00 |
| Sep 30, 2025 | 554,650.00 |
| Jun 30, 2025 | 1.06 Mn |
| Jun 30, 2025 | 1.06 Mn |